PL3825690T3 - Sposób hodowli pojedynczych limfocytów b - Google Patents

Sposób hodowli pojedynczych limfocytów b

Info

Publication number
PL3825690T3
PL3825690T3 PL20214670.0T PL20214670T PL3825690T3 PL 3825690 T3 PL3825690 T3 PL 3825690T3 PL 20214670 T PL20214670 T PL 20214670T PL 3825690 T3 PL3825690 T3 PL 3825690T3
Authority
PL
Poland
Prior art keywords
cultivation method
cell cultivation
cell
cultivation
Prior art date
Application number
PL20214670.0T
Other languages
English (en)
Inventor
Josef Endl
Sonja Offner
Josef Platzer
Natalie Schuhmacher
Basile Siewe
Irmgard Thorey
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3825690T3 publication Critical patent/PL3825690T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1185—Thymus cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL20214670.0T 2010-05-28 2011-05-26 Sposób hodowli pojedynczych limfocytów b PL3825690T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10005602.7A EP2400298B1 (en) 2010-05-28 2010-05-28 Single B-cell cultivation method and specific antibody production

Publications (1)

Publication Number Publication Date
PL3825690T3 true PL3825690T3 (pl) 2025-10-27

Family

ID=42396427

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10005602T PL2400298T3 (pl) 2010-05-28 2010-05-28 Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał
PL20214670.0T PL3825690T3 (pl) 2010-05-28 2011-05-26 Sposób hodowli pojedynczych limfocytów b
PL17169362T PL3239708T3 (pl) 2010-05-28 2011-05-26 Sposób hodowania pojedynczego limfocytu b

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10005602T PL2400298T3 (pl) 2010-05-28 2010-05-28 Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17169362T PL3239708T3 (pl) 2010-05-28 2011-05-26 Sposób hodowania pojedynczego limfocytu b

Country Status (14)

Country Link
US (4) US20130084637A1 (pl)
EP (4) EP2400298B1 (pl)
JP (3) JP5779239B2 (pl)
KR (1) KR101495976B1 (pl)
CN (2) CN105039252B (pl)
BR (1) BR112012025695B1 (pl)
CA (2) CA2798286C (pl)
DK (1) DK2400298T3 (pl)
ES (4) ES2434256T3 (pl)
MX (2) MX2012013437A (pl)
PL (3) PL2400298T3 (pl)
RU (1) RU2709531C2 (pl)
SI (1) SI2400298T1 (pl)
WO (1) WO2011147903A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2612910C2 (ru) 2011-12-21 2017-03-13 Ф. Хоффманн-Ля Рош Аг Быстрый способ клонирования и экспрессии сегментов гена родственной вариабельной области антитела
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
ES2786253T3 (es) 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
US20140287952A1 (en) * 2013-03-15 2014-09-25 Alderbio Holdings Llc Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
CN104232577B (zh) * 2013-06-20 2017-12-01 中国人民解放军军事医学科学院基础医学研究所 一种获得自身反应性b细胞的方法
AU2014370516B9 (en) * 2013-12-24 2021-07-29 Kling Biotherapeutics B.V. Ex vivo antibody production
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP7026634B2 (ja) 2016-03-30 2022-02-28 エフ．ホフマン－ラ ロシュ アーゲー Ｂ細胞培養法
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
CN106222137A (zh) * 2016-08-24 2016-12-14 南昌大学 一种体外活化人记忆性b细胞成浆细胞的培养方法
JP7252627B2 (ja) 2016-12-15 2023-04-05 デューク ユニバーシティ 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
EP3562936B1 (en) 2017-01-02 2024-05-22 F. Hoffmann-La Roche AG B-cell cultivation method
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
EP3625332B1 (en) 2017-05-19 2022-02-02 F. Hoffmann-La Roche AG Method for the production of thymocyte supernatant
CN111295784B (zh) * 2017-11-08 2024-02-23 夏普株式会社 空气电池用负极、空气电池及空气电池的制造方法
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
CN108588019B (zh) * 2018-05-03 2019-04-02 首都医科大学附属北京朝阳医院 一种体外诱导初始b细胞分化为调节性b细胞的方法及其培养条件
CN109234232A (zh) * 2018-09-30 2019-01-18 杭州华安单抗生物技术有限公司 兔外周血b细胞的培养体系及培养方法、抗体的制备方法和应用
WO2020141145A1 (en) * 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
KR102871135B1 (ko) * 2019-04-08 2025-10-14 엑셀라 바이오사이언시스 인코포레이티드 미세모세관 어레이를 이용하는 스크리닝 방법 및 시스템
WO2021211997A1 (en) * 2020-04-16 2021-10-21 The General Hospital Corporation B cell immunomodulatory therapy for acute respiratory distress syndrome
CN111518765B (zh) * 2020-05-12 2021-01-26 优睿赛思(武汉)生物科技有限公司 一种b淋巴细胞体外培养体系及应用
WO2022047381A1 (en) * 2020-08-31 2022-03-03 Genentech, Inc. Methods for producing antibodies
WO2022170074A1 (en) * 2021-02-05 2022-08-11 Amgen Inc. Enhanced hybridoma generation
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use
CN120917139A (zh) 2023-04-05 2025-11-07 豪夫迈·罗氏有限公司 用于抗体表达细胞的体外培养方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116678A (ja) * 1981-12-28 1983-07-11 Ajinomoto Co Inc 浮遊性動物細胞の培養法およびその装置
JPS58216125A (ja) * 1982-06-09 1983-12-15 Asahi Chem Ind Co Ltd ヒト抗体の産生方法
WO1991016418A1 (en) * 1990-04-17 1991-10-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Feeder cells for monoclonal antibody production
US5387940A (en) * 1993-07-07 1995-02-07 Rca Thomson Licensing Corporation Method and apparatus for providing scaleable compressed video signal
WO1995013089A1 (en) * 1993-11-10 1995-05-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by b lymphocytes
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
JP4231688B2 (ja) * 2000-08-16 2009-03-04 タカラバイオ株式会社 抗原特異的細胞傷害性ｔ細胞拡大培養方法
US20060051348A1 (en) 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US20070031550A1 (en) 2005-08-15 2007-02-08 Samson Allan D Method for continuously processing meat substrates
AU2006290736B2 (en) * 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
AU2006304387A1 (en) * 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
NZ600075A (en) * 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
ES2367322T3 (es) * 2005-12-16 2011-11-02 Ribovax Biotechnologies Sa Métodos para obtener células inmortalizadas que secretan anticuerpos.
EP2021463B1 (en) * 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
US8642307B2 (en) 2006-05-25 2014-02-04 Nalge Nunc International Corporation Cell culture surface chemistries
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
US8394583B2 (en) * 2008-07-24 2013-03-12 The Board Of Regents Of The University Of Texas System VH4 codon signature for multiple sclerosis
EP2352763B2 (en) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
ES2525346T3 (es) * 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
EP2233502A1 (en) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies

Also Published As

Publication number Publication date
SI2400298T1 (sl) 2013-11-29
PL3239708T3 (pl) 2021-06-14
RU2012153785A (ru) 2014-07-10
CN102918395A (zh) 2013-02-06
EP2577304B1 (en) 2017-05-10
EP2400298B1 (en) 2013-08-14
US20180298335A1 (en) 2018-10-18
MX345884B (es) 2017-02-22
CN105039252B (zh) 2019-05-28
ES3039652T3 (en) 2025-10-23
HK1212731A1 (zh) 2016-06-17
EP3825690B1 (en) 2025-07-23
CA2798286C (en) 2019-05-28
KR101495976B1 (ko) 2015-02-25
JP2013526286A (ja) 2013-06-24
CA3008822A1 (en) 2011-12-01
JP5779239B2 (ja) 2015-09-16
US20160251621A1 (en) 2016-09-01
CN105039252A (zh) 2015-11-11
JP2017169579A (ja) 2017-09-28
RU2015155197A3 (pl) 2019-07-17
KR20130030758A (ko) 2013-03-27
US20130084637A1 (en) 2013-04-04
EP2577304A1 (en) 2013-04-10
JP6204415B2 (ja) 2017-09-27
RU2709531C2 (ru) 2019-12-18
JP6353953B2 (ja) 2018-07-04
ES2858450T3 (es) 2021-09-30
MX2012013437A (es) 2013-01-22
EP2400298A1 (en) 2011-12-28
EP3239708B1 (en) 2021-01-06
ES2632928T3 (es) 2017-09-18
RU2015155197A (ru) 2019-01-16
JP2015211690A (ja) 2015-11-26
BR112012025695A2 (pt) 2016-07-05
EP3239708A1 (en) 2017-11-01
EP3825690C0 (en) 2025-07-23
US20210062149A1 (en) 2021-03-04
DK2400298T3 (da) 2013-09-02
CA3008822C (en) 2020-08-25
WO2011147903A1 (en) 2011-12-01
HK1181112A1 (en) 2013-11-01
PL2400298T3 (pl) 2014-01-31
ES2434256T3 (es) 2013-12-16
CN102918395B (zh) 2015-09-09
BR112012025695B1 (pt) 2022-06-21
EP3825690A1 (en) 2021-05-26
CA2798286A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
PL3239708T3 (pl) Sposób hodowania pojedynczego limfocytu b
GB201001833D0 (en) Method
GB201004759D0 (en) Method
GB201007353D0 (en) Method
GB201011513D0 (en) Method
GB201007354D0 (en) Method
HU1000330D0 (en) Novel method
ZA201304243B (en) Improved connecting method
GB2486031B (en) Attachment method
GB201019086D0 (en) Bacterial methods
GB201006306D0 (en) Method
GB201012148D0 (en) Method
GB201012784D0 (en) Method
GB201010855D0 (en) Method
GB201007207D0 (en) Method
GB201017003D0 (en) Method
GB201007522D0 (en) Method
GB201016857D0 (en) Culture method
GB201009203D0 (en) Irrigation method
GB201014285D0 (en) Method
GB201014632D0 (en) Method
GB201017574D0 (en) Method
GB201016858D0 (en) Method
GB201014556D0 (en) Method
GB201004760D0 (en) Method